nenocorilant (CORT125236) / Corcept Therap - LARVOL DELTA

Nenocorilant in Combination with Immunotherapy (Businesswire) - "SYNERGY - Enrollment continues in Phase 1b dose-finding trial of nenocorilant plus nivolumab in 30 patients with a variety of solid tumors - Results expected by the end of next year."

Enrollment status • P1 data • Solid Tumor

SYNERGY: A phase 1b/2 study of nenocorilant, a selective glucocorticoid receptor antagonist, plus nivolumab in patients with advanced solid malignancies. (ASCO 2026) - P1/2 | "Safety endpoints will be summarized using descriptive statistics and time-to-event endpoints will be estimated using Kaplan-Meier methods. Data from the currently enrolling phase 1b part of the study will inform the dosing regimen for phase 2, which will further characterize the anticancer activity and safety of nenocorilant + nivolumab in specific solid malignancies."

Clinical • Metastases • P1/2 data • Oncology • Ovarian Cancer • Solid Tumor • CD8

Corcept Therapeutics...reported its results for the quarter ended March 31, 2026. (Corcept Therapeutics Press Release) - "STELLA – Initiated Phase 2 trial of relacorilant plus nab-paclitaxel in 50 patients with cervical cancer (received one or two prior lines of therapy), conducted in collaboration with ARCAGY-GINECO; TRIDENT – Enrollment continues in Phase 2 trial of relacorilant plus nab-paclitaxel and gemcitabine as first-line therapy in 60 patients with pancreatic cancer...SYNERGY – Enrollment continues in Phase 1b dose-finding trial of nenocorilant plus nivolumab in 30 patients with a variety of solid tumors...Prostate cancer – Enrollment continues in randomized, placebo-controlled Phase 2 trial of relacorilant plus enzalutamide in 90 patients with early-stage prostate cancer, conducted in collaboration with the University of Chicago"

Trial status • Cervical Cancer • Pancreatic Cancer • Prostate Cancer

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1/2 | N=50 | Recruiting | Sponsor: Corcept Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1/2 | N=50 | Not yet recruiting | Sponsor: Corcept Therapeutics

New P1/2 trial • Oncology • Solid Tumor

Nenocorilant in Combination with Immunotherapy (Businesswire) - "Solid tumors - Phase 1b dose-finding trial of nenocorilant, our proprietary selective glucocorticoid receptor antagonist, plus nivolumab in 30 patients with a variety of solid tumors to begin in coming weeks - nenocorilant’s first study in patients."

New P1 trial • Solid Tumor